Bone Biologics Corporation (BBLG)
| Previous Close | 1.6000 |
| Open | 1.5900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.5000 - 1.6080 |
| 52 Week Range | 1.5000 - 72.0000 |
| Volume | |
| Avg. Volume | 82,101 |
| Market Cap | 1.363M |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -34.0100 |
| Earnings Date | May 06, 2024 - May 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.50 |
- Business Wire
Bone Biologics Announces Closing of $2.0 Million Public Offering
BURLINGTON, Mass., March 06, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lie
- Business Wire
Bone Biologics Announces Pricing of $2.0 Million Public Offering
BURLINGTON, Mass., March 04, 2024--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share (or common stock equivalent in lieu thereof) and accomp
- Business Wire
Bone Biologics Reports Progress With NB1 Clinical Program
BURLINGTON, Mass., March 01, 2024--Bone Biologics Corporation (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion. Following Human Research Ethics Committee (HREC) approval last year in Australia for the multicenter, prospective, randomized pilot clinical trial, the Company reports that three hospital sites have been engaged to participate in the pilot clinical tria
